Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) | 78144-2

Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) | 78144-2 | Gentaur US, UK & Europe Disrtribition

Category: Coronavirus/Lentivirus

Application: 1. Study the mechanism of viral transduction of SARS-CoV-2 (P.1) variant.
2. Screening for neutralizing antibodies for SARS-CoV-2 Spike (P.1 variant) and ACE2.

Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection.

Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility.

Product Type: Lentivirus

Shippement Condition: -80°C